$2.390
-0.059 (-2.45%)At close
EQ News
EQ Events
Equillium CEO: Significant Progress on EQ504 Towards Clinic
"We continue to make meaningful progress advancing EQ504 toward the clinic," said Bruce Steel, Chief Executive Officer of Equillium. "Our colon-targeted formulated product has been manufactured, and we plan to submit the dossier for our Phase 1 study in Australia imminently. We expect to initiate this study in the fourth quarter of 2026 and report topline data approximately six months thereafter. The study is designed as a conventional randomized, double-blind, placebo-controlled single and multiple ascending dose study (SAD/MAD) in healthy volunteers, focused on safety, tolerability, pharmacokinetics and pharmacodynamics to assess proof of mechanism. Subject to supportive Phase 1 data, we anticipate expeditiously initiating a placebo-controlled study to assess the safety, tolerability, and efficacy of EQ504 in patients with moderately to severely active ulcerative colitis. Key study parameters are intended to leverage other AhR modulator clinical datasets in ulcerative colitis to facilitate an efficient patient proof-of-concept study."
Equillium Appoints Snehal Naik as Chief Development Officer
Equillium appointed Snehal Naik as chief development officer. Naik will lead clinical development and medical strategy across Equillium's pipeline, with responsibility for advancing EQ504 into the clinic and progressing future programs. Most recently, Naik served as senior VP and head of clinical development at Ventyx Biosciences.
Equillium CEO Highlights Potential of EQ504 in Preclinical Data
"Following our March year-end update and financing, we have remained focused on advancing EQ504 toward the clinic while continuing to expand the scientific foundation supporting its differentiated profile," said Bruce Steel, CEO of Equillium. "Recent preclinical data presented at IMMUNOLOGY2026 further strengthen our growing body of evidence for EQ504's ability to modulate immune responses while promoting epithelial repair and barrier restoration. We believe these attributes reinforce the potential of EQ504 as a potentially differentiated, non-immunosuppressive therapeutic approach in ulcerative colitis and other inflammatory diseases."
Equillium Files to Sell 18.88M Shares of Common Stock
Equillium files to sell 18.88M shares of common stock for holders
Equillium Cash and Short-term Investments Total $30.3M
Cash, cash equivalents and short-term investments totaled $30.3M as of December 31, 2025, compared to $22.6M as of December 31, 2024. Equillium believes that its cash and cash equivalents on the balance sheet as of December 31, 2025, together with the recently completed financing of $35M in March, are capable of funding its currently planned operations into 2029, based on certain assumptions and estimates that may prove to be inaccurate. "2025 was a transformative year as we sharpened our strategic focus on EQ504 and strengthened our financial position to support its advancement into the clinic," said Bruce Steel, CEO of Equillium. "Our financing in August 2025 of up to $50 million, together with our recently completed $35 million financing, further reinforces confidence in our strategy and provides the resources to efficiently execute our EQ504 clinical development plan. With operating runway expected into 2029, we are well-positioned to advance EQ504's differentiated, non-immunosuppressive approach targeting the AhR pathway to address significant unmet needs across inflammatory diseases, and we believe it has the potential to be a best-in-class oral therapy in ulcerative colitis, with additional opportunities across gastrointestinal and inflammatory lung diseases."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.